<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic silencing of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor genes (TSG) inactivates TSG functions </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we identified PCDH10 as a methylated TSG in <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we detected its frequent silencing and methylation in <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines including 100% Burkitt, 100% diffuse large B cell, 86% Hodgkin, 100% nasal natural killer/T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 1/3 of <z:mpath ids='MPATH_336'>leukaemia</z:mpath> cell lines, and in <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e> but not in <z:mpath ids='MPATH_458'>normal</z:mpath> peripheral blood mononuclear cells or lymph nodes </plain></SENT>
<SENT sid="3" pm="."><plain>PCDH10 silencing could be reversed by demethylation with <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Methylation was further detected in 14% of Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> sera </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, PCDH10 methylation is frequently involved in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> and could serve as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-specific biomarker </plain></SENT>
</text></document>